StockWatch
·
FORTIS HEALTHCARE LTD. · QQ2 FY-2027 · THE CALL

Strong growth, margin pressure; PAT declined despite 17% revenue rise

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsFORTISFORTIS HEALTHCARE LTD.10 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

Margin guidance intact but qualified; near-term caution warranted. PAT miss signals integration/cost headwinds.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Fortis delivered strong 17% revenue growth and improving EBITDA margins, but profit declined 2.5% YoY—indicating execution stress from ESOP, new unit ramp-up, and drug price controls. Bed expansion strategy is concrete (500+ beds FY27, 2,000 by FY30) but near-term margins remain under pressure.

₹2735 Cr

Revenue · +17.3% YoY

₹320.5 Cr

Reported PAT · −2.5% YoY

Expanding

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Hospital revenue 18.6% YoY to ₹2,340 Cr

MET

Q2 delivered supports this; hospital segment driving growth

Diagnostics 12.2% YoY growth to ₹448 Cr gross

MET

Confirmed in transcript; slower than hospital growth

EBITDA margins improving to 24.2% vs 23.9% YoY

MET

Operating EBITDA ₹663 Cr at 24.2% margin reported; YoY expansion

PAT growth 4% to ₹317 Cr pre-exceptional

OVERSTATED

Delivered PAT ₹320.5 Cr shows -2.5% YoY decline; exceptional items and NPM 11.7% suggest margin dilution

500+ beds expected FY27; 2,000 beds total expansion

MET

Suguna 110 beds + brownfield 200/year mentioned; 2,000-bed target by FY30

Earnings quality

What changed since the last call

Deltas vs. the prior call

Margin guidance qualification

Neutral

Management says 'margin guidance more or less intact' but refrained from FY28 guidance due to drug price control and ramp-up uncertainties. Cautious signal vs prior confidence.

Bed expansion acceleration

Upgrade

Now targeting 500+ beds FY27 (vs 400 from prior call) with Suguna acquisition; 2,000-bed multi-year expansion by FY30 with clear mechanisms (greenfield ₹400 Cr, brownfield ₹3,500 Cr CAPEX committed)

Diagnostics growth guidance reiterated

Maintained

Held 12-13% growth guidance for FY27; Q2 achieved 12.2%, wellness segment now 15% of revenue (vs 13% prior year), B2C mix 54% (vs 52%)

The Q&A

Analysts pressed hard on margins (Dhvani Shah, DSP; Neha Manpuria, BOFA), occupancy bottlenecks (Abdulkader Puranwala, ICICI), and acquisition strategy (Saion Mukherjee, Nomura). Management held ground on strategy but candidly conceded near-term margin uncertainties and drug price control impact, declining specific FY28 guidance.

The exchanges that mattered

Bed expansion greenfield timing — Neha Manpuria, Bank of America

Partial

400-bed agreement with Seth Sunder Lal Jain Charitable Eye Hospital Society; partnership model; capex ₹3,500 Cr committed over brownfield/greenfield; 3-4 year timeline. One greenfield ₹400 Cr Delhi hospital coming over next 4 years.

Bangalore occupancy ramp-up — Abdulkader Puranwala, ICICI Securities

Partial

Suguna is community/secondary care hospital; serves micro-market cluster alongside larger units. Different formats required for different patient profiles. Occupancy will improve; financially performing well. No near-term margin drag.

FMRI progress and profitability — Neha Manpuria, Bank of America

Partial

New block waiting for final approvals; should commission soon. Attracted good clinical talent in last months. Radiation oncology facility expected by February (Q4 FY27). Currently producing low-double-digit EBITDA; expect jump when oncology added.

Drug price control impact — Dhvani Shah, DSP Mutual Fund

Dodged

Very difficult to assess exact quantum; circular very recent. One-third of oncology revenue exposed; some drugs profitable, some not. Calculating impact; will not give specific margin guidance until clarity. Expect margin flattish end-FY27, TBD for FY28.

Margin guidance and FY28 outlook — Neha Manpuria, Bank of America

Dodged

Margin guidance 'more or less remains intact.' Challenges exist: FMRI OP pending, Manesar and People Tree in ramp-up, drug price controls uncertain. Will not comment on FY28 margin now; refrain from guidance due to uncertainty. Expect flattish EBITDA margin end-FY27.

Diagnostics growth bridging peer gap — Shyam Srinivasan, Goldman Sachs

Partial

Wellness now 15% of revenue (up from 13%), specialized growing. B2C up to 54% (from 52%). Focused on deep-market penetration, more centers, mid-teens growth target. Volume growth will improve with initiatives in specialized testing and B2C expansion.

IHH stake increase constraint — Atul Minocha, Independent Investor

Answered

Supreme Court FY23 decision cleared IHH to increase stake. Forensic audit is separate; no constraint to IHH stake. Audit ordered by court, timeline 6 months. Constraint is IHH's decision on capex/dividend needs, not legal.

Gleaneagles O&M footprint and margin — Damayanti Kurai, HSBC

Answered

One year to stabilize operations; focused on recruiting doctors, facility upgrades, IT systems. Operations nearly flat; expect improvement from next year. Stabilization first, margin recovery later.

Guidance

Forward guidance and management's confidence

Diagnostics FY27: 12-13% growth (reiterated)

Medium

Q2 achieved 12.2%. Wellness acceleration and specialized testing expansion supporting mid-teens long-term, but near-term held at 12-13%.

Hospital bed expansion: 500+ beds FY27; 2,000 beds by FY30

High

Suguna 110 beds live; brownfield ~200 beds/year for next 2 years; greenfield ₹400 Cr Delhi hospital in pipeline. Committed CAPEX ₹3,500 Cr.

Hospital EBITDA 25% target FY28 (post-ESOP offset) — maintained

Low

Management says 'margin guidance more or less intact' but heavily qualified. New units (Manesar, People Tree) in ramp-up; FMRI OP pending. Refrained from FY28 margin guidance.

FY27 year-end EBITDA margin expected flattish

Medium

Currently 24.2% in Q2; Vivek said expect EBITDA margin 'flattish' end-FY27 due to ramp-up costs and drug price control uncertainties.

Committed CAPEX ₹3,500 Cr for brownfield/greenfield expansion

High

Spread over 3-3.5 years; includes Suguna (₹270 Cr), greenfield Delhi (₹400 Cr), brownfield facilities at Mohali, Shalimar Bagh, and others.

Risks the call surfaced

Ranked by how much they should concern a holder

Regulatory & pricing

High

137 oncology drugs under price cap; one-third of oncology revenue (~₹60-70 Cr) exposed. Impact magnitude unquantified. Management acknowledged 'very difficult' to assess.

Execution

High

FMRI flagship ₹200 Cr project not yet operationalized; Manesar and People Tree still in ramp-up with margin drag. Bangalore acquisition occupancy only 63%.

Operational

High

PAT declined 2.5% YoY despite 17% revenue growth. ESOP (₹140 Cr FY27) masking underlying margins. Drug price controls, ramp-up costs, and cost inflation pressuring profitability.

Financial

Medium

Net debt ₹2,188 Cr (0.87x EBITDA). Committed CAPEX ₹3,500 Cr over 3-3.5 years requires debt/internal accrual. Risks if revenue growth or margins miss guidance.

Legal

Low

Forensic audit ordered by court; 6-month timeline. IHH stake increase possible but pending legal clarity. Overhang could delay strategic decisions.

Management

Score 7/10. Clear and candid on challenges. Refrained from speculative guidance (FY28 margin) pending drug price control clarity. Direct answers on most questions; some deflection on oncology margin impact timing. Mixed. Revenue growth 17.3% strong; EBITDA margin +30 bps YoY. But PAT flat/down and new unit ramp-up delayed vs history suggest execution friction. FMRI OP still pending.

What to watch next
  • 1 · Q3 FY27

    FMRI operational profitability; oncology impact clarity from drug price controls

  • 2 · Q4 FY27

    Manesar radiation oncology facility commissioning; People Tree ramp-up progress

  • 3 · FY28

    Two brownfield expansions (Mohali, Shalimar Bagh) completion; bed expansion to 2,000+ units

Bed expansion strategy is concrete (500+ beds FY27, 2,000 by FY30) but near-term margins remain under pressure.

Informational and educational content only. Not investment advice.